A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02964936

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02964936
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02964936. Randomized; no masking; primary purpose treatment. Start 2017-01-11 (actual); primary completion 2018-08-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
Intervention (Drug)
roxadustat
Lead sponsor
Astellas Pharma Inc (class: industry)
Collaborator
Kyntra Bio (class: industry)

Record details

Record id
cardio:ct-nct02964936
Content hash
5500c4349dc2f99a9d13516182360b1ec0660a2e520e16470d779d130d0b6735